Dr. Giannelou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
267 Grant St
Bridgeport, CT 06610Phone+1 203-384-3000
Education & Training
National Institutes of Health Clinical CenterFellowship, Rheumatology, 2012 - 2014
Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 2009 - 2012
University of Patras School of MedicineClass of 2004
Certifications & Licensure
NY State Medical License 2019 - 2025
MD State Medical License 2012 - 2018
Publications & Presentations
PubMed
- 6 citationsA phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.Wolfgang A Schmidt, Bhaskar Dasgupta, Jennifer Sloane, Angeliki Giannelou, Yuqing Xu
Arthritis Research & Therapy. 2023-10-16 - 25 citationsSarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.Robert F Spiera, Sebastian Unizony, Kenneth J Warrington, Jennifer Sloane, Angeliki Giannelou
The New England Journal of Medicine. 2023-10-05 - 3 citationsEfficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.Sumathi Sivapalasingam, David J Lederer, Rafia Bhore, Negin Hajizadeh, Gerard Criner
Clinical Infectious Diseases. 2022-08-24
Authored Content
- Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)November 2022
Press Mentions
Case Reports: CINCA SyndromeDecember 22nd, 2014
Professional Memberships
- Fellows-in-Training 3rd year
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
